Hasil Pencarian - Stephen T Barclay

  • Menampilkan 1 - 8 hasil dari 8
Perbaiki Hasil
  1. 1
    The Value of Quantitative Faecal Immunochemical Testing as a Prioritisation Tool for the Endoscopic Investigation of Patients With Iron Deficiency

    The Value of Quantitative Faecal Immunochemical Testing as a Prioritisation Tool for the Endoscopic Investigation of Patients With Iron Deficiency oleh William Clackett, Stephen T. Barclay, Adrian J. Stanley, Aidan Cahill

    Diterbitkan 2021-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Competing Risk Bias in Prognostic Models Predicting Hepatocellular Carcinoma Occurrence: Impact on Clinical Decision-making

    Competing Risk Bias in Prognostic Models Predicting Hepatocellular Carcinoma Occurrence: Impact on Clinical Decision-making oleh Hamish Innes, Philip Johnson, Scott A. McDonald, Victoria Hamill, Alan Yeung, John F. Dillon, Peter C. Hayes, April Went, Stephen T. Barclay, Andrew Fraser, Andrew Bathgate, David J. Goldberg, Sharon J. Hutchinson

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Tracking TCRβ sequence clonotype expansions during antiviral therapy using high-throughput sequencing of the hypervariable region

    Tracking TCRβ sequence clonotype expansions during antiviral therapy using high-throughput sequencing of the hypervariable region oleh Mark W Robinson, Mark W Robinson, Joseph eHughes, Gavin S Wilkie, Rachael eSwann, Rachael eSwann, Stephen T Barclay, Peter R Mills, Arvind H Patel, Emma C Thomson, John eMcLauchlan

    Diterbitkan 2016-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Characterisation of a Hepatitis C Virus Subtype 2a Cluster in Scottish PWID with a Suboptimal Response to Glecaprevir/Pibrentasvir Treatment

    Characterisation of a Hepatitis C Virus Subtype 2a Cluster in Scottish PWID with a Suboptimal Response to Glecaprevir/Pibrentasvir Treatment oleh Rajiv Shah, Stephen T. Barclay, Erica S. Peters, Ray Fox, Rory Gunson, Amanda Bradley-Stewart, Samantha J. Shepherd, Alasdair MacLean, Lily Tong, Vera Jannie Elisabeth van Vliet, Michael Ngan Chiu Bong, Ana Filipe, Emma C. Thomson, Chris Davis

    Diterbitkan 2022-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection

    Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection oleh Hamish Innes, Peter Jepsen, Scott McDonald, John Dillon, Victoria Hamill, Alan Yeung, Jennifer Benselin, April Went, Andrew Fraser, Andrew Bathgate, M. Azim Ansari, Stephen T. Barclay, David Goldberg, Peter C. Hayes, Philip Johnson, Eleanor Barnes, William Irving, Sharon Hutchinson, Indra Neil Guha

    Diterbitkan 2021-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virus.

    Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virus. oleh Aminata Sy, Leanne McCabe, Emma Hudson, Azim M Ansari, Vincent Pedergnana, Shang-Kuan Lin, S Santana, Marzia Fiorino, Aftab Ala, Ben Stone, M Smith, Mark Nelson, Stephen T Barclay, Stuart McPherson, Stephen D Ryder, Jane Collier, Eleanor Barnes, Ann Sarah Walker, Sarah L Pett, Graham Cooke, STOP-HCV-1 trial team

    Diterbitkan 2023-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C [version 2; peer review: 2 approved]

    Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C [version 2; peer review: 2 approved] oleh Graham S. Cooke, Sarah Pett, Leanne McCabe, Chris Jones, Richard Gilson, Sumita Verma, Stephen D. Ryder, Jane D. Collier, Stephen T. Barclay, Aftab Ala, Sanjay Bhagani, Mark Nelson, Chinlye Ch'Ng, Ben Stone, Martin Wiselka, Daniel Forton, Stuart McPherson, Rachel Halford, Dung Nguyen, David Smith, Azim Ansari, Emily Dennis, Fleur Hudson, Eleanor J. Barnes, Ann Sarah Walker

    Diterbitkan 2021-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT

    Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT oleh Graham S Cooke, Sarah Pett, Leanne McCabe, Christopher Jones, Richard Gilson, Sumita Verma, Stephen D Ryder, Jane D Collier, Stephen T Barclay, Aftab Ala, Sanjay Bhagani, Mark Nelson, Chin Lye Ch’Ng, Benjamin Stone, Martin Wiselka, Daniel Forton, Stuart McPherson, Rachel Halford, Dung Nguyen, David Smith, M Azim Ansari, Helen Ainscough, Emily Dennis, Fleur Hudson, Eleanor J Barnes, Ann Sarah Walker, the STOP-HCV trial team

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: